Epstein-Barr Virus (LMP)
Product Code:
EB100
EB100
Host Type:
Mouse
Mouse
Antibody Isotype:
IgG1
IgG1
Antibody Clonality:
Monoclonal
Monoclonal
Antibody Clone:
CS1-4 Cocktail
CS1-4 Cocktail
Regulatory Status:
RUO
RUO
Target Species:
Epstein-Barr virus (EBV)
Epstein-Barr virus (EBV)
Applications:
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
2-8°C
2-8°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| EB100 | 1 ml | £586.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Netherlands.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Applications Description:
IHC(C, P)
Background:
The antibody cocktail is positive for the latent membrane protein-1 (LMP1) of the Epstein-Barr Virus. It strongly reacts with EBV-infected lymphoblastoid cell lines and infected B-cell immunoblasts in infectious Mononucleose and atypical lymphoproliferations in immunosuppressed patients. It is positive in app. 25-30 % undifferentiated nasopharyngeal carcinomas and in 40-50% of Hodgkin's diseases. Due to the lack of LMP in Burkitt's disease the cocktail is unreactive with these cells. Epstein Barr Virus is a member of the herpes viridae family and is involved in the development of infectious mononucleosis. EBV infections are also discussed in connection with the induction of several tumours. Generally EBV is found in Burkitt's lymphoma and in nasopharyngeal carcinoma. Additionally it is found in 40-50 % of Hodgkin lymphoma and app. 20-30 % of anaplastic CD30+ large cell lymphoma. Hydrophilic C-terminal end of the 60 kDa late membrane protein 1 of Eppstein Barr Virus.
Caution:
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
Concentration:
50 ?g/ml
Immunogen:
Fusion protein of beta-galactosidase and EBV-late membrane antigen
Incubation Time:
60 min at RT
Pre-Treatment:
For pre-treatment Pronase (0,1%) is recommended, however unmasking on citrate basis (DE000) or glycol basis (DE007) will also improve the staining intensity. Cryostat sections and cell smears should be fixed with acetone since the antibody will not react with native antigen.
Product:
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 ?l working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method:
Antibody solution in stabilizing phosphate buffer pH 7.3. Contains 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 ?l working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Secondary Reagents:
We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity:
Epstein Barr Virus
Working Concentration:
(liquid conc.) 1:10 - 1:20
Documents
References
1. Rowe M., Rowe D.T., Gregory C.D., Young L.S., Farrell P.J., Rupani H., et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma. EMBO J. 6; 2743-2453.
2. 2. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., et al. (1990) Epstein-Barr virus in nasal T-cell lymphomaas in patients with lethal midline granuloma. Lancet 335; 128-130.
3. Herbst H. Dallenbach F. Hummel M., Niedobietek G. Finn T., Young L.S., et al. (19919 Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphoma.
4. Murray P.G., Young L.S., Rowe M., and Crocker J. (1992) Immunohistochemical demonstration of the Epstein-Barr virus encoded latent membrane protein in paraffin sections of Hodgkin's disease. J. Pathol. 166; 1-5.
2. 2. Harabuchi Y., Yamanaka N., Kataura A., Imai S., Kinoshita T., Mizuno F., et al. (1990) Epstein-Barr virus in nasal T-cell lymphomaas in patients with lethal midline granuloma. Lancet 335; 128-130.
3. Herbst H. Dallenbach F. Hummel M., Niedobietek G. Finn T., Young L.S., et al. (19919 Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphoma.
4. Murray P.G., Young L.S., Rowe M., and Crocker J. (1992) Immunohistochemical demonstration of the Epstein-Barr virus encoded latent membrane protein in paraffin sections of Hodgkin's disease. J. Pathol. 166; 1-5.